Display options
Share it on

ISRN Hepatol. 2013 Sep 22;2013:959474. doi: 10.1155/2013/959474. eCollection 2013.

NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis.

ISRN hepatology

Vi Nguyen, Rob Zielinski, Paul Harnett, Katherine Miller, Henry Chan, Nikitha Vootakuru, Priya Acharya, Montaha Khan, Oliver Gibbs, Sarika Gupta, Anjla Devi, Shani Phillips, Jacob George, David van der Poorten

Affiliations

  1. Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  2. Department of Medical Oncology, Westmead Hospital, Sydney, NSW 2145, Australia.
  3. Department of Medicine, Westmead Hospital, Sydney, NSW 2145, Australia.
  4. Department of Gastroenterology & Hepatology, Westmead Hospital, Sydney, NSW 2145, Australia.

PMID: 27335835 PMCID: PMC4890870 DOI: 10.1155/2013/959474

Abstract

Background. N-terminal probrain natriuretic peptide (NT-proBNP) is a hormone involved in the regulation of cardiovascular homeostasis. Changes in serum NT-proBNP during large volume paracentesis (LVP) in patients with ascites have never before been examined. Aims. To determine if significant changes in serum NT-proBNP occur in patients undergoing LVP and the associated clinical correlates in patients with cirrhosis. Method. A total of 45 patients with ascites were prospectively recruited. Serum NT-proBNP, biochemistry, and haemodynamics were determined at baseline and at key time points during and after paracentesis. Results. 34 patients were analysed; 19 had ascites due to cirrhosis and 15 from malignancy. In those with cirrhosis, NT-proBNP decreased by 77.3 pg/mL at 2 L of drainage and 94.3 pg/mL at the end of paracentesis, compared with an increase of 10.5 pg/mL and 77.2 pg/mL in cancer patients at the same time points (P = 0.05 and P = 0.03). Only congestive cardiac failure (CCF) was an independent predictor of significant NT-proBNP changes at the end of drainage in cirrhotic patients (P < 0.01). There were no significant changes in haemodynamics or renal biochemistry for either group. Conclusion. Significant reductions in serum NT-proBNP during LVP occur in patients with cirrhosis but not malignancy, and only comorbid CCF appeared to predict such changes.

References

  1. J Hepatol. 2010 Sep;53(3):397-417 - PubMed
  2. Ann Oncol. 2001 Oct;12(10):1353-7 - PubMed
  3. Hepatology. 2012 Apr;55(4):1172-81 - PubMed
  4. Liver Int. 2010 Aug;30(7):937-47 - PubMed
  5. Liver Int. 2010 Aug;30(7):1059-66 - PubMed
  6. Transplant Proc. 2011 Jun;43(5):1684-90 - PubMed
  7. Gut. 2003 Oct;52(10):1511-7 - PubMed
  8. Semin Liver Dis. 2008 Feb;28(1):43-58 - PubMed
  9. Hepatology. 2009 Jun;49(6):2087-107 - PubMed
  10. Clin Gastroenterol Hepatol. 2006 Nov;4(11):1385-94 - PubMed
  11. J Clin Gastroenterol. 2010 Jan;44(1):e23-6 - PubMed
  12. Hepatology. 1997 Nov;26(5):1131-7 - PubMed
  13. Gastroenterology. 1990 Jan;98(1):146-51 - PubMed
  14. Gastroenterology. 1996 Oct;111(4):1002-10 - PubMed
  15. Scand J Clin Lab Invest. 1997 Oct;57(6):529-40 - PubMed
  16. Gut. 2008 Feb;57(2):268-78 - PubMed
  17. J Hepatol. 1997 Oct;27(4):645-53 - PubMed
  18. Gastroenterology. 1997 Aug;113(2):579-86 - PubMed
  19. N Engl J Med. 1994 Feb 3;330(5):337-42 - PubMed
  20. Gastroenterology. 1988 Jun;94(6):1493-502 - PubMed
  21. J Gastroenterol Hepatol. 2005 Jul;20(7):1115-20 - PubMed

Publication Types